

AD

ADVERTISEMENT

ASCO Breakthrough AUGUST 3-5, 2023 YOKOHAMA, JAPAN & ONLINE | #ASCOBT23

EARLY REGISTRATION DEADLINE: JUNE 28, 2023

REGISTER TODAY >

Journal of Clinical Oncology®

An American Society of Clinical Oncology Journal



- Log In
- Submit
- E-Alerts
- Cart

[OpenAthens/Shibboleth >](#)

≡ MENU Q

[Journal of Clinical Oncology](#) > [List of Issues](#) > [Volume 30, Issue 15 suppl](#) >

Meeting Abstract | 2012 ASCO Annual Meeting I

Article Tools

DEVELOPMENTAL THERAPEUTICS—EXPERIMENTAL THERAPEUTICS

Endoxifen for breast cancer: Multiple-dose, dose-escalation study characterizing pharmacokinetics and safety in metastatic breast cancer patients.

[Ateeq Ahmad](#) , [S. Sheikh](#) , [R. Nagarkar](#) , [J. K. Singh](#) , [S. Krishnan](#) , [S. Shrivastav](#)...

[Show More](#)

[Abstract Disclosures](#)

Abstract

3089^

Background: Endoxifen is an active metabolite of tamoxifen, a drug used in the treatment of breast cancer. To be clinically effective, tamoxifen must be converted to endoxifen by CYP2D6. Direct administration of endoxifen would not be subject to pharmacogenetic variations or drug-drug interactions. Our preclinical studies (Breast Cancer Treat 122, 579-584, 2010) have validated the concept of using endoxifen for the treatment of breast cancer. In human (Clin. Pharmacol. Ther. 88, 814-817, 2010), the single oral doses tested up to 4 mg of endoxifen were safe, well tolerated and bioavailable.

Methods: A multiple-dose escalating study was conducted in 3 cohorts and each cohort had 6 patients (18 metastatic breast cancer patients). Endoxifen at 3 dose levels (2, 4, or 8 mg) was given once daily for 28 days. Routine laboratory tests, vital signs and electrocardiograms were measured throughout the study. Blood samples for PK analysis were collected after 28 days post dose. Endoxifen in plasma samples was determined using LC-MS/MS. **Results:** Endoxifen was found to be safe up to

OPTIONS & TOOLS

- [Export Citation](#)
- [Track Citation](#)
- [Add To Favorites](#)
- [Rights & Permissions](#)



ADVERTISEMENT

ASCO Breakthrough

August 3-5, 2023 | #ASCOBT23
Yokohama, Japan & Online

EARLY REGISTRATION DEADLINE: JUNE 28, 2023

REGISTER TODAY

COMPANION ARTICLES

No companion articles

ARTICLE CITATION

DOI:
10.1200/jco.2012.30.15_suppl.3089
Journal of Clinical Oncology 30,
no. 15_suppl (May 20, 2012) 3089-3089.

Published online May 20, 2012.

8.0 mg. At steady state, it displays dose-proportional PK with respect to C_{max} and AUC (see Table below). **Conclusions:** Multiple daily endoxifen doses of 4.0-8.0 mg resulted in endoxifen exposures that would be sufficient for effective therapy. The favorable safety and multiple-dose PK profile of endoxifen warrants further evaluation of safety and efficacy of endoxifen in breast cancer patients.

Pharmacokinetics parameters of endoxifen in metastatic breast cancer patients (n=5) after multiple-dose of 2, 4 or 8 mg of endoxifen tablets.

Parameters (units)	Mean ± SD		
	2 mg	4 mg	8 mg
T_{max} (h)*	5 (3.0-12.0)	5 (4.0-6.0)	5 (4.0-6.0)
$C_{min_{ss}}$ (ng/mL)	15.7±6.4	44.0±11.6	80.4±26.7
$C_{max_{ss}}$ (ng/mL)	24.5 ±7.3	75.9 ±18.5	134.1±32.1
AUC_{tau} (ng.h/mL)	445.3 ±146.2	1363.3±396.3	2322.6±619.8
PTF (%)	50.8±19.0	56.5 ±17.9	57.6 ±14.6
$C_{av_{ss}}$ (ng/mL)	18.6 ±6.1	56.8 ±16.5	96.8±25.8


*Data presented as median (range)
© 2012 by American Society of Clinical Oncology

ADVERTISEMENT

For Your Patients

ASCO Answers
Guide to Caring for a Loved One With Cancer

Help Prepare Caregivers for This Challenging Role



Cancer.Net

ASCO Career Center

Medical Oncologist/Hematologist

Anchorage, Alaska | Competitive compensation package

Seeking a full-time board certified/board eligible medical Oncologist/Hematologist.

Employer: Alaska Oncology and Hematology
[Apply for this job >](#)

Academic Surgical Oncologist Position in Illinois

Champaign-Urbana, Illinois | Commensurate with experience

The University of Illinois (in collaboration w/ Carle Health) is seeking a Surgical Oncologist to join the Carle Illinois College of Medicine.

Employer: Carle Physician Group
[Apply for this job >](#)

Director

Chicago, Illinois | DOE

RUSH seeks a highly collaborative and visionary physician leader to serve as its next

ADVERTISEMENT

ASCO Breakthrough

August 3-5, 2023 | #ASCOBT23
Yokohama, Japan & Online

EARLY REGISTRATION DEADLINE: JUNE 28, 2023
[REGISTER TODAY >](#)



QUICK LINKS

Content

Newest Articles
Archive
Meeting Abstracts

Journal Information

About
Editorial Roster
Contact Us
Permissions

Resources

Authors
Reviewers
Subscribers
Institutions
Advertisers

[Submit Your Manuscript](#)

[Subscribe to this Journal](#)



ASCO FAMILY OF SITES

Journals

Journal of Clinical Oncology
JCO Oncology Practice
JCO Global Oncology
JCO Clinical Cancer Informatics
JCO Precision Oncology

Publications

ASCO Educational Book
ASCO Daily News
ASCO Connection
The ASCO Post

Education

ASCO eLearning
ASCO Meetings
Cancer.Net

Other Sites

ASCO.org
ASCO Author Services
ASCO Career Center
CancerLinQ
Conquer Cancer Foundation
TAPUR Study

